Breast Cancer

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Experts reflect on the power of clinical trial participation, multidisciplinary collaboration, and innovation to personalize care.

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

Katherine C. Ansley, MD, discusses the role of oral SERDs and PI3K and AKT inhibitors for the treatment of metastatic breast cancer.

Researchers are leading the nation in using powerful and precise radioactive drugs to treat people with complex cancers.

Experts explore how advances in systemic therapy are helping personalize and de-escalate breast cancer treatment.

Experts discuss how coordinated clinical trial participation enables safer treatment de-escalation and advances breast cancer care through research efforts.

Experts discuss how coordinated tumor board reviews enhance continuity of care, treatment personalization, and patient confidence after breast cancer surgery.

Experts discuss how involving plastic surgeons and genetic counselors early in breast cancer care helps guide personalized surgical decisions.

Aditya Bardia, MD, MPH, discusses how Dato‑DXd serves as a new treatment option with a distinct safety profile in HR-positive, HER2‑negative breast cancer.

Panelists discuss how treatment algorithms should differentiate between primary and secondary endocrine resistance, disease burden, and mutation status while looking forward to future combinations with oral selective estrogen receptor degraders (SERDs) and next-generation PIK3CA inhibitors with improved toxicity profiles to enable more effective precision medicine approaches.

Panelists discuss how to manage PIK3CA inhibitor toxicities through frequent early monitoring, patient education about warning signs, use of continuous glucose monitors (CGMs) when needed, and willingness to interrupt treatment and reduce doses while maintaining patients on therapy long term.

Gedatolisib triplet and doublet regimens cut the risk of progression by up to 76% vs fulvestrant in HR-positive/HER2-negative advanced breast cancer.

Experts discuss the importance of early multidisciplinary collaboration in breast cancer care, particularly involving radiation oncology at diagnosis.

Experts discuss how a multidisciplinary clinic streamlines care and improves treatment planning for patients with newly diagnosed breast cancer.

The top 5 OncLive videos of the week cover insights in multiple myeloma, breast cancer, melanoma, and CLL/SLL.

Kelly E. McCann, MD, PhD, details the current standard of care and novel approaches for the treatment of ER-positive, HER2-negative advanced breast cancer.

The European Commission has approved inavolisib plus palbociclib/fulvestrant in PIK3CA-mutant ER-positive, HER2-negative advanced breast cancer.

Panelists discuss how the SERENA-6 trial’s approach of serial liquid biopsy monitoring for ESR1 mutations raises important questions about the optimal timing and clinical benefit of molecularly guided therapy switches, with both experts preferring to see overall survival data before changing practice patterns.

Panelists discuss how biomarker testing strategies have evolved from second-line to first-line metastatic disease, driven by the availability of targeted agents for PIK3CA and ESR1 mutations, with both tissue and liquid biopsy approaches being used to ensure timely results for treatment decision-making.

PF-07248144 is a first-in-class selective inhibitor of KAT6A and KAT6B that has displayed the ability to suppress ER expression in a preclinical study.

Hope S. Rugo, MD, discusses the safety profile of alpelisib for the treatment of PI3K-mutant HR-positive/HER2-negative advanced breast cancer.

Panelists discuss how nonclinical factors including drug costs, insurance coverage, work situations, patient intelligence for complex dosing schedules, and comprehensive pretreatment education about toxicities like hyperglycemia, rash, and diarrhea are crucial for successful implementation of the triplet regimen.

Panelists discuss how to identify ideal candidates for triplet therapy using a case example, emphasizing the importance of endocrine resistance, disease burden, performance status, and careful management of hyperglycemia risk through baseline hemoglobin A1C (HbA1C) assessment and proactive glucose monitoring strategies.

Jade E. Jones, MD, discusses the importance of identifying the most effective first-line treatment regimen for PD-L1–positive TNBC.